Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision was updated from v3.5.2 to v3.5.3, representing a small, non-substantive update to the page. The core study details and data are not indicated to have changed.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays Revision: v3.5.2, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision: v3.5.0 has been added and revision v3.4.3 has been removed.SummaryDifference0.1%

- Check61 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check90 days agoChange DetectedRevision: v3.4.2 was added and the prior funding notice (v3.4.1) was removed; there are no changes to study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check97 days agoChange DetectedA government funding/status notice was added to the page footer and the site revision updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.